5 completed, 1 active not recruiting, 1 terminated. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Active not recruiting 1, Terminated 1 |
| Phase 2 | 4 | Completed 3, Active not recruiting 1 |
Follow Relapsed Diffuse Large B-cell Lymphoma: new trials by email Literature Review of Relapsed Diffuse Large B-cell Lymphoma trials Research Report on Relapsed Diffuse Large B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab Ociperlimab, Tislelizumab, Rituximab - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Completed | BeiGene | 53 | 2022-04-25 | 2025-09-15 |
| Copanlisib Plus Venetoclax in R/R DLBCL Copanlisib, Venetoclax - Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 48 | 2021-09-08 | 2026-01-07 |
| A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma INCB053914, INCB050465 - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | Incyte Corporation | 9 | 2018-12-03 | 2020-11-10 |
| Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL Ipilimumab, Nivolumab - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | Icahn School of Medicine at Mount Sinai | 6 | 2018-05-14 | 2023-02-15 |
| A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 400mg ABT-199, Ibrutinib, Rituximab - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Hackensack Meridian Health | 10 | 2017-09-05 | 2024-09-23 |
| Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide - Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Kite, A Gilead Company | 307 | 2015-04-21 | 2024-06-04 |
| Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Ibrutinib, Lenalidomide, Rituximab - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Pharmacyclics LLC. | 138 | 2014-03-13 | 2022-02-04 |
Lymphoma, Large B-Cell, Diffuse (7) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoma, B-Cell (7) · Lymphoproliferative Disorders (7) · Neoplasms by Histologic Type (7) · Lymphoma (6) · Lymphoma, Non-Hodgkin (6) · Neoplasms (6)
Rituximab (4) · ibrutinib (2) · venetoclax (2) · Bendamustine Hydrochloride (1) · Carboplatin (1) · Cisplatin (1) · Cyclophosphamide (1) · Dexamethasone (1) · Doxorubicin (1) · Etoposide (1) · Gemcitabine (1) · Ifosfamide (1) · Ipilimumab (1) · Lenalidomide (1) · Levetiracetam (1)
BeiGene (1) · Dana-Farber Cancer Institute (1) · Hackensack Meridian Health (1) · Icahn School of Medicine at Mount Sinai (1) · Incyte Corporation (1) · Kite, A Gilead Company (1) · Pharmacyclics LLC. (1)
United States (6) · Germany (2) · Belgium (1) · Canada (1) · China (1) · France (1) · Israel (1) · Netherlands (1) · United Kingdom (1)
Andre Goy, MD (1) · Fred Zheng, MD (1) · Jennifer Crombie, MD (1) · Joshua Brody, MD (1) · Jutta K. Neuenburg, MD, PhD (1)
PMID 29226797, PMID 30518502, PMID 31331917, PMID 33035333, PMID 33334730, PMID 34296427, PMID 34310745, PMID 34493319, PMID 34515338, PMID 36618900, PMID 36821768, PMID 38635762, PMID 39240498
2015 (1)